239 related articles for article (PubMed ID: 24518168)
1. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers.
Gastaldi R; Poggi E; Mussa A; Weber G; Vigone MC; Salerno M; Delvecchio M; Peroni E; Pistorio A; Corrias A
J Pediatr; 2014 May; 164(5):1189-1194.e1. PubMed ID: 24518168
[TBL] [Abstract][Full Text] [Related]
2. Thyroid-stimulating hormone receptor antibodies during follow-up as remission markers in childhood-onset Graves' disease treated with antithyroid drugs.
Wang SY; Wang CT; Tien KJ; Chang CC; Liu TH
Kaohsiung J Med Sci; 2020 Apr; 36(4):281-286. PubMed ID: 31849168
[TBL] [Abstract][Full Text] [Related]
3. [Long-term follow up after antithyroid drug treatment in Graves' disease].
Wille T; Müller B; Noth D; Bürgi U; Diem P
Praxis (Bern 1994); 2006 Jul; 95(29-30):1121-7. PubMed ID: 16916174
[TBL] [Abstract][Full Text] [Related]
4. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.
Vitti P; Rago T; Chiovato L; Pallini S; Santini F; Fiore E; Rocchi R; Martino E; Pinchera A
Thyroid; 1997 Jun; 7(3):369-75. PubMed ID: 9226205
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
Cappelli C; Gandossi E; Castellano M; Pizzocaro C; Agosti B; Delbarba A; Pirola I; De Martino E; Rosei EA
Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
[TBL] [Abstract][Full Text] [Related]
6. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
Bojarska-Szmygin A; Ciechanek R
Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
[TBL] [Abstract][Full Text] [Related]
7. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.
Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):248-53. PubMed ID: 15314994
[TBL] [Abstract][Full Text] [Related]
8. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
9. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission.
Konishi T; Okamoto Y; Ueda M; Fukuda Y; Harusato I; Tsukamoto Y; Hamada N
Endocr J; 2011; 58(2):95-100. PubMed ID: 21206137
[TBL] [Abstract][Full Text] [Related]
10. Graves' disease: evolution and prognosis after eight months of treatment with methimazole.
Gauna AT; Guillén CE; Sartorio GC; Soto RJ
Medicina (B Aires); 1992; 52(3):207-12. PubMed ID: 1364158
[TBL] [Abstract][Full Text] [Related]
11. Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene.
Kinjo Y; Takasu N; Komiya I; Tomoyose T; Takara M; Kouki T; Shimajiri Y; Yabiku K; Yoshimura H
J Clin Endocrinol Metab; 2002 Jun; 87(6):2593-6. PubMed ID: 12050220
[TBL] [Abstract][Full Text] [Related]
12. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
[TBL] [Abstract][Full Text] [Related]
13. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
[TBL] [Abstract][Full Text] [Related]
14. Antithyroid drug treatment for graves' disease in children: a long-term retrospective study at a single institution.
Ohye H; Minagawa A; Noh JY; Mukasa K; Kunii Y; Watanabe N; Matsumoto M; Suzuki M; Yoshihara A; Ito K; Ito K
Thyroid; 2014 Feb; 24(2):200-7. PubMed ID: 23926918
[TBL] [Abstract][Full Text] [Related]
15. Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment.
Liu X; Shi B; Li H
Ann Endocrinol (Paris); 2015 Dec; 76(6):679-83. PubMed ID: 26514949
[TBL] [Abstract][Full Text] [Related]
16. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
Rink T; Holle LH; Schroth HJ; Garth H
Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
[TBL] [Abstract][Full Text] [Related]
19. [The prognostic value of thyroid stimulating antibodies after antithyroid drug treatment of Graves' disease].
Li J; Gao H; Xu L
Zhonghua Yi Xue Za Zhi; 1994 Apr; 74(4):218-20, 254-5. PubMed ID: 7922762
[TBL] [Abstract][Full Text] [Related]
20. TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs.
Okamoto Y; Tanigawa S; Ishikawa K; Hamada N
Endocr J; 2006 Aug; 53(4):467-72. PubMed ID: 16820704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
